行情

FCSC

FCSC

Fibrocel Science
NASDAQ

实时行情|Nasdaq Last Sale

2.960
0.000
0.00%
已收盘, 16:00 10/23 EDT
开盘
2.964
昨收
2.960
最高
2.970
最低
2.960
成交量
1.15万
成交额
--
52周最高
3.280
52周最低
1.450
市值
2,888.47万
市盈率(TTM)
51.66
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FCSC 新闻

  • 收盘:美股小幅上扬 苹果创纪录新高
  • 新浪美股.57分钟前
  • 微软第一财季营收331亿美元 净利同比增21%
  • 新浪科技.1小时前
  • 黄金期货周三收高0.6% 四日来首次上涨
  • 新浪美股.1小时前
  • BMO:美联储有能力阻止货币市场基金转投逆回购工具
  • 新浪美股.2小时前

更多

所属板块

生物技术和医学研究
+0.09%
制药与医学研究
-0.25%

热门股票

名称
价格
涨跌幅

FCSC 简况

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
展开

Webull提供Fibrocell Science Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。